BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Javid Sadri Nahand, Farah Bokharaei‐Salim, Arash Salmaninejad, Abolfazl Nesaei, Fatemeh Mohajeri, Azadeh Moshtzan, Alireza Tabibzadeh, Mohammad Karimzadeh, Mohsen Moghoofei, Arezo Marjani, Shoeleh Yaghoubi, Hossein Keyvani. microRNAs: Key players in virus‐associated hepatocellular carcinomaJournal of Cellular Physiology 2019; 234(8): 12188 doi: 10.1002/jcp.27956
2
Enze Jiang, Anna Junjie Shangguan, Shuangshuang Chen, Lin Tang, Shuang Zhao, Zhenghong Yu. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinomaCancer Letters 2016; 379(2): 262 doi: 10.1016/j.canlet.2015.07.016
3
Sandra Coenen, Suzanne van Meer, Jan M. Vrolijk, Clemens Richter, Karel J. van Erpecum, Marijke C. Mostert, Irene K. Veldhuijzen, Jurriën G. P. Reijnders, Hanneke van Soest, Kees Dirksen, Joost P. H. Drenth, René P. M. Koene, Maaike Bosschart, Pieter Friederich, Martijn J. ter Borg, Rick H. P. J. Daemen, Joop E. Arends, Marc A. M. T. Verhagen, Christine Schout, B. W. Marcel Spanier. Clinical impact of five large-scale screening projects for chronic hepatitis B in Chinese migrants in the NetherlandsLiver International 2016; 36(10): 1425 doi: 10.1111/liv.13125
4
D. A. Fernández-Galindo, F. Sánchez-Ávila, L. Bobadilla-Morales, P. Gómez-Quiróz, M. Bueno-Topete, J. Armendáriz-Borunda, L. V. Sánchez-Orozco. New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype HJournal of Medical Virology 2015; 87(6): 985 doi: 10.1002/jmv.24098
5
Yuanyuan Kong, Hong You, Jidong Jia. Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common senseHepatology International 2016; 10(2): 239 doi: 10.1007/s12072-016-9714-9